Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Daily News

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

Todd Neale

December 08, 2017

Presentation TCT 2017

Anticoagulation Following DVT/PE Intervention: What, When, Why, and for How Long?

Presenter: Michael R. Jaff, Robert A. Lookstein, Teresa L. Carman

October 30, 2017

Presentation TCT 2017

Research Opportunities in PE Therapy

Presenter: Michael R. Jaff, Robert A. Lookstein

October 30, 2017

Presentation TCT 2017

Techniques and Outcomes of PE Lysis: Is Catheter-Directed Thrombolysis Really Better Than IV Lytics?

Presenter: Michael R. Jaff, Robert A. Lookstein, Jay S. Giri

October 30, 2017

Presentation TCT 2017

Is PE Really a Team Sport? Benefits and Disadvantages of PERT

Presenter: Michael R. Jaff, Robert A. Lookstein, Kenneth Rosenfield

October 30, 2017

Presentation TCT 2017

Iliac Vein Compression: Indications and Techniques for Venous Stents (Case Reviews)

Presenter: Michael R. Jaff, Robert A. Lookstein, Sanjiv Lakhanpal

October 30, 2017

Presentation TCT 2017

Optimal Techniques for Catheter-Directed Thrombolysis

Presenter: Michael R. Jaff, Robert A. Lookstein

October 30, 2017

Presentation TCT 2017

What Does ATTRACT Mean for Catheter-Directed Thrombolysis for DVT?

Presenter: Michael R. Jaff, Robert A. Lookstein, Barry T. Katzen

October 30, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

News Daily News

Data on IVC Filters Sparse but Somewhat Reassuring: Meta-Analysis

Caitlin E. Cox

September 19, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

L.A. McKeown

September 11, 2017

News Conference News ISET 2017

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

Caitlin E. Cox

February 10, 2017

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

Todd Neale

February 08, 2017

Presentation ISET 2017

Anticoagulation Following DVT: Agents and Length of Treatment

Presenter: Ian del Conde

February 04, 2017

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2017

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

Anticoagulation Following DVT/PE Intervention: What, When, Why, and for How Long?

Research Opportunities in PE Therapy

Techniques and Outcomes of PE Lysis: Is Catheter-Directed Thrombolysis Really Better Than IV Lytics?

Is PE Really a Team Sport? Benefits and Disadvantages of PERT

Iliac Vein Compression: Indications and Techniques for Venous Stents (Case Reviews)

Optimal Techniques for Catheter-Directed Thrombolysis

What Does ATTRACT Mean for Catheter-Directed Thrombolysis for DVT?

TCTMD’s Top 10 Most Popular Stories for September 2017

Data on IVC Filters Sparse but Somewhat Reassuring: Meta-Analysis

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

Anticoagulation Following DVT: Agents and Length of Treatment

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content